BR0308737A - Pró-drogas de fosfato de fluoroxindóis - Google Patents
Pró-drogas de fosfato de fluoroxindóisInfo
- Publication number
- BR0308737A BR0308737A BR0308737-9A BR0308737A BR0308737A BR 0308737 A BR0308737 A BR 0308737A BR 0308737 A BR0308737 A BR 0308737A BR 0308737 A BR0308737 A BR 0308737A
- Authority
- BR
- Brazil
- Prior art keywords
- fluoroxindole
- phosphate prodrugs
- enantiomer
- phosphate
- prodrugs
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title abstract 2
- 239000010452 phosphate Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"PRó-DROGAS DE FOSFATO DE FLUOROXINDóIS". A presente invenção refere-se a novos derivados de fosfato tendo a Fórmula (I) geral, em que a ligação ondulada (b) representa o racemato, o enanciómero (R) ou o enanciómero (S) e A, B, R^ 1^, R^ 2^, R^ 3^, R^ 4^, m e n são como definidos aqui, ou um sal ou solvato não-tóxico, farmaceuticamente aceitável, dos mesmos, e são úteis no tratamento de distúrbios que são sensíveis à abertura dos canais de potássio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36601002P | 2002-03-20 | 2002-03-20 | |
| PCT/US2003/008613 WO2003080047A1 (en) | 2002-03-20 | 2003-03-20 | Phosphate prodrugs of fluorooxindoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308737A true BR0308737A (pt) | 2005-01-11 |
Family
ID=28454740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308737-9A BR0308737A (pt) | 2002-03-20 | 2003-03-20 | Pró-drogas de fosfato de fluoroxindóis |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6930100B2 (pt) |
| EP (1) | EP1485085A4 (pt) |
| JP (1) | JP4359150B2 (pt) |
| KR (1) | KR100951499B1 (pt) |
| CN (1) | CN100384820C (pt) |
| BR (1) | BR0308737A (pt) |
| CA (1) | CA2479256A1 (pt) |
| CO (1) | CO5611143A2 (pt) |
| GE (1) | GEP20074230B (pt) |
| HR (1) | HRP20040853A2 (pt) |
| IL (2) | IL164022A0 (pt) |
| IS (1) | IS7456A (pt) |
| MX (1) | MXPA04008999A (pt) |
| NO (1) | NO20044442L (pt) |
| NZ (1) | NZ535365A (pt) |
| PL (1) | PL372413A1 (pt) |
| RS (1) | RS81904A (pt) |
| RU (1) | RU2312857C2 (pt) |
| UA (1) | UA77296C2 (pt) |
| WO (1) | WO2003080047A1 (pt) |
| ZA (1) | ZA200407337B (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
| US6916937B2 (en) * | 2003-02-03 | 2005-07-12 | Bristol-Myers Squibb Company | Carbohydrate prodrugs of fluorooxindoles |
| CA2533377C (en) | 2003-07-30 | 2012-11-27 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| US7169803B2 (en) * | 2004-03-15 | 2007-01-30 | Bristol-Myers Squibb Company | N-substituted prodrugs of fluorooxindoles |
| US7253167B2 (en) | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| JP4801096B2 (ja) | 2005-01-19 | 2011-10-26 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用 |
| US8227455B2 (en) * | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| JP4981673B2 (ja) * | 2005-09-13 | 2012-07-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物およびその製造方法 |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| WO2009100090A1 (en) * | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Prodrugs of cgrp receptor antagonist |
| US8188119B2 (en) | 2008-10-24 | 2012-05-29 | Eisai R&D Management Co., Ltd | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same |
| AU2010266040B2 (en) * | 2009-06-25 | 2015-01-15 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds |
| EP4124616A1 (en) | 2009-06-25 | 2023-02-01 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| US8592427B2 (en) * | 2010-06-24 | 2013-11-26 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| KR101974793B1 (ko) | 2015-07-06 | 2019-05-02 | 길리애드 사이언시즈, 인코포레이티드 | Cot 조정제 및 그의 사용 방법 |
| PE20211305A1 (es) | 2018-01-05 | 2021-07-20 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas |
| CN112423754A (zh) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | 阿立哌唑的给药策略 |
| EP4364727A3 (en) * | 2018-03-05 | 2024-05-15 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| TW202235416A (zh) | 2019-06-14 | 2022-09-16 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| CA3146385A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| PE20220563A1 (es) | 2019-07-10 | 2022-04-13 | Cybrexa 2 Inc | Conjugados peptidicos de citotoxinas como terapeuticos |
| US11845737B2 (en) | 2020-04-02 | 2023-12-19 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
| EP3912625A1 (en) | 2020-05-20 | 2021-11-24 | Kaerus Bioscience Limited | Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234947A (en) | 1991-11-07 | 1993-08-10 | New York University | Potassium channel activating compounds and methods of use thereof |
| US5187173A (en) * | 1991-12-27 | 1993-02-16 | Sterling Winthrop Inc. | 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| NZ505515A (en) | 1997-12-31 | 2003-03-28 | Univ Kansas | Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof |
| CA2318817A1 (en) * | 1998-01-29 | 1999-08-05 | Bristol-Myers Squibb Company | Phosphate derivatives of diaryl 1,3,4-oxadiazolone |
-
2003
- 2003-03-20 BR BR0308737-9A patent/BR0308737A/pt not_active IP Right Cessation
- 2003-03-20 RU RU2004131201/04A patent/RU2312857C2/ru not_active IP Right Cessation
- 2003-03-20 UA UA20041109513A patent/UA77296C2/uk unknown
- 2003-03-20 CN CNB038109778A patent/CN100384820C/zh not_active Expired - Fee Related
- 2003-03-20 NZ NZ535365A patent/NZ535365A/en not_active IP Right Cessation
- 2003-03-20 RS YUP-819/04A patent/RS81904A/sr unknown
- 2003-03-20 EP EP03711659A patent/EP1485085A4/en not_active Withdrawn
- 2003-03-20 PL PL03372413A patent/PL372413A1/xx not_active Application Discontinuation
- 2003-03-20 US US10/393,031 patent/US6930100B2/en not_active Expired - Lifetime
- 2003-03-20 WO PCT/US2003/008613 patent/WO2003080047A1/en active Application Filing
- 2003-03-20 MX MXPA04008999A patent/MXPA04008999A/es active IP Right Grant
- 2003-03-20 CA CA002479256A patent/CA2479256A1/en not_active Abandoned
- 2003-03-20 GE GEAP8458A patent/GEP20074230B/en unknown
- 2003-03-20 IL IL16402203A patent/IL164022A0/xx active IP Right Grant
- 2003-03-20 KR KR1020047014626A patent/KR100951499B1/ko not_active IP Right Cessation
- 2003-03-20 JP JP2003577875A patent/JP4359150B2/ja not_active Expired - Fee Related
-
2004
- 2004-09-12 IL IL164022A patent/IL164022A/en not_active IP Right Cessation
- 2004-09-13 ZA ZA200407337A patent/ZA200407337B/en unknown
- 2004-09-17 IS IS7456A patent/IS7456A/is unknown
- 2004-09-17 HR HRP20040853 patent/HRP20040853A2/xx not_active Application Discontinuation
- 2004-09-20 CO CO04093294A patent/CO5611143A2/es not_active Application Discontinuation
- 2004-10-19 NO NO20044442A patent/NO20044442L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2312857C2 (ru) | 2007-12-20 |
| IL164022A0 (en) | 2005-12-18 |
| KR20040106293A (ko) | 2004-12-17 |
| US20030195169A1 (en) | 2003-10-16 |
| MXPA04008999A (es) | 2004-12-07 |
| WO2003080047A1 (en) | 2003-10-02 |
| CO5611143A2 (es) | 2006-02-28 |
| CN1652769A (zh) | 2005-08-10 |
| RU2004131201A (ru) | 2005-05-10 |
| RS81904A (en) | 2007-02-05 |
| IS7456A (is) | 2004-09-17 |
| ZA200407337B (en) | 2006-02-22 |
| US6930100B2 (en) | 2005-08-16 |
| IL164022A (en) | 2008-04-13 |
| AU2003215017A1 (en) | 2003-10-08 |
| CA2479256A1 (en) | 2003-10-02 |
| HRP20040853A2 (en) | 2004-12-31 |
| KR100951499B1 (ko) | 2010-04-07 |
| CN100384820C (zh) | 2008-04-30 |
| EP1485085A4 (en) | 2007-03-14 |
| NO20044442L (no) | 2004-10-19 |
| GEP20074230B (en) | 2007-11-12 |
| EP1485085A1 (en) | 2004-12-15 |
| JP4359150B2 (ja) | 2009-11-04 |
| JP2005526097A (ja) | 2005-09-02 |
| PL372413A1 (en) | 2005-07-25 |
| NZ535365A (en) | 2006-07-28 |
| UA77296C2 (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308737A (pt) | Pró-drogas de fosfato de fluoroxindóis | |
| BR0315296A (pt) | Derivados do ciclohexanol espirocìclicos | |
| BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
| BR0307998A (pt) | Hidroxietilaminas substituìdas | |
| BRPI0408561A (pt) | métodos para manufatura de 2'-desoxi-59-l-nucleosìeos | |
| CY1110745T1 (el) | Παραγωγα πυρρολιδονης ως αναστολεις μαοβ | |
| AU2003211560A1 (en) | Novel phenylalanine derivative | |
| BR0206381A (pt) | Derivados do ácido fumárico como inibidor de nf-kappab | |
| HU9600834D0 (en) | Quinazoline derivatives | |
| TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
| ATE260255T1 (de) | 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate | |
| BRPI0411900A (pt) | compostos antivirais e métodos | |
| BR0115452A (pt) | Compostos tendo atividade fungicida e processos para fabricação e uso dos mesmos | |
| TR200100432T2 (tr) | Hepatit C inhibitörü tri-peptidler | |
| ES2179071T3 (es) | Agentes vasodilatadores perifericos que comprenden como principio activo derivados de la piperidina 4-amino n-acilada. | |
| BR0205889A (pt) | Pirazolopirimidinas como agentes tepapêuticos | |
| NO20012567L (no) | Azepinoindolderivater, fremstilling og anvendelse derav | |
| BR0307071A (pt) | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico | |
| ATE408601T1 (de) | Fredericamycin-derivate | |
| BR0307060A (pt) | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico | |
| CY1111851T1 (el) | Αρωματικες ενωσεις ως αντι-φλεγμονωδεις, ανοσορυθμιστικοι και αντι-πολλαπλασιαστικοι παραγοντες | |
| EA200000204A1 (ru) | Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов | |
| TR199700206A2 (xx) | Floralkil- ve floralkoksi ikame edilmi� heterosiklik bradikinin-antagonistleri, bunlar�n imal edilmesine mahsus usul ve bunlar�n kullan�lmalar�. | |
| BR9916807A (pt) | Antagonistas de 5ht1 para terapia antidepressiva | |
| DK1056754T3 (da) | Phosphatderivater af diaryl-1,3,4-oxadiazolon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA:INT.CI. A61K 31/40, A61P 25/06 Ipc: A61K 31/40 (2011.01), A61P 25/06 (2011.01) |
|
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A, 10A E 11A ANUIDADES. |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |